Earnings Snapshot: Teva Pharmaceutical Industries tops Q4 estimates; initiates FY 2025 outlook

*Other Operating Data Consensus Source: Bloomberg

More on Teva Pharmaceutical Industries Limited:

• Teva Pharmaceutical Non-GAAP EPS of $0.71 beats by $0.01, revenue of $4.23B beats by $110M

• Top 4 Immunology Stocks Poised For Growth In 2025
• Duvakitug And Teva’s Growth: A Game Changer In Pharma
• FDA accepts Teva, Alvotech BLAs for Simponi biosimilars